The anti-tumor agent erastin induces oxidative, non-apoptotic death in human tumor cells with mutations in the oncogenes HRAS, KRAS, or BRAF. Using affinity-based target identification and MS/MS analysis, Yagoda et al. (82) identified VDAC2 and VDAC3 as the docking sites for erastin binding to mitochondria. This evidence concerns the gene BRAF and neoplasm.